A heart-wrenching plea is echoing across Victoria, demanding that the meningococcal B vaccine be made free for all, following the sudden and devastating death of 16-year-old Levi Syer-Peterson. But here’s where it gets controversial: while some states in Australia already fund this vaccine, Victorian families are left to shoulder the hefty cost of up to $600 for their children’s protection. This disparity has sparked a fierce debate about equity in healthcare and the value we place on young lives. And this is the part most people miss: the meningococcal B infection often masquerades as a common bug, making it a silent but deadly threat, especially to babies and teenagers. Levi’s mother, Norliah Syer-Peterson, is now leading a passionate campaign, backed by the Royal Australian College of General Practitioners (RACGP), to ensure no other family endures her unimaginable loss. 'If something’s preventable, what are we waiting for?' she asks, her grief fueling a call to action. The RACGP’s Victoria chair, Dr. Anita Munoz, sharply criticizes the current approach, questioning why we wait for a certain number of deaths before acting. 'It’s a difficult reality for the public to accept,' she says, 'that economic considerations seem to outweigh the urgency of saving lives.' Here’s the kicker: the vaccine, Bexsero®, is already available for free to specific at-risk groups through the National Immunisation Program (NIP), but its broader rollout hinges on a complex process involving the Pharmaceutical Benefits Advisory Committee (PBAC) and the pharmaceutical giant GlaxoSmithKline (GSK). While GSK has previously sought NIP listing, their last submission was in 2019, leaving many to wonder why progress has stalled. The Victorian government, meanwhile, insists it’s engaging with GSK and welcomes further submissions, but the ball remains in the company’s court. Bold question for you: Should pharmaceutical companies hold the power to decide who gets access to life-saving vaccines, or should governments step in to ensure universal protection? Levi’s story is a stark reminder that meningococcal B is not just a statistic—it’s a real, preventable threat that can strike anyone. As Syer-Peterson’s petition gains momentum, the question lingers: How many more lives must be lost before action is taken? Share your thoughts in the comments—this is a conversation we can’t afford to ignore.
